New nevirapine label underscores the risk for hepatotoxicity in key populations.
D018791:CD4 Lymphocyte Count; D004348:Drug Labeling; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D019829:Nevirapine / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine